Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
Not Confirmed
Not Confirmed
12-14 August, 2025
Not Confirmed
Not Confirmed
17-21 August, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
Industry Trade Show
Not Confirmed
12-14 August, 2025
Industry Trade Show
Not Confirmed
17-21 August, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
05 Aug 2025
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/vertexs-trial-failure-scrapped-study-cloud-pain-drug-push-shares-slump-2025-08-04/
04 Aug 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250804131004/en/Vertex-Reports-Second-Quarter-2025-Financial-Results
04 Aug 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250804247622/en/Vertex-Announces-Results-from-Phase-2-Study-of-VX-993-for-the-Treatment-of-Acute-Pain
21 Jul 2025
// HEALTH CANADA
14 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250714775266/en/Vertex-Announces-Broad-Reimbursement-Agreement-With-NHS-England-for-ALYFTREK-DeutivacaftorTezacaftorVanzacaftor-an-Innovative-Once-Daily-CFTR-Modulator-for-the-Treatment-of-Cystic-Fibrosis
14 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250714536618/en/Vertex-Named-a-Premier-Inc.-Breakthroughs-Innovation-Celebration-Winner-for-JOURNAVX-a-First-in-Class-Non-Opioid-Treatment-for-Adults-With-Moderate-to-Severe-Acute-Pain
Inspections and registrations
ABOUT THIS PAGE